MedPage Today -- Patients taking the Parkinson’s drug combo carbidopa/levodopa and entacapone (Stalevo) may be at a higher risk for cardiovascular events such as myocardial infarction, stroke, and death, the FDA said in a prepared statement.
MedPage Today -- Patients taking the Parkinson’s drug combo carbidopa/levodopa and entacapone (Stalevo) may be at a higher risk for cardiovascular events such as myocardial infarction, stroke, and death, the FDA said in a prepared statement.